InsidersTradesSigma
Explore the complete record of transactions filed by Landsittel Michael, Chief Financial Officer. Director active across 1 companies, notably Blueprint Medicines Corp. Aggregated, 2 disclosures have been published. Total volume traded: €72k. The latest transaction was disclosed on 3 March 2022 — Cession. Regulator: SEC (Form 4). The full history is openly available.
2 of 2 declarations
Michael Landsittel is the Chief Financial Officer of Blueprint Medicines Corp. In this role, he is responsible for the company's financial management, including financial planning and reporting. Michael Landsittel brings expertise in corporate finance and financial strategy, thereby contributing to the growth and sustainability of Blueprint Medicines Corp.